IGF-1 claims on TikTok: what the evidence actually supports

What did @diagoslab actually say?

@diagoslab called IGF-1 "the closest thing to science playing God" and claimed it causes the body to "explode with growth" in ways that amount to "absolute mutation." The creator also warned that IGF-1 "drains your blood sugar like gasoline on fire" and framed the compound as something that makes users feel "superhuman" at serious physical cost. The video's hashtags, including "gear," signal this is aimed at performance-enhancement audiences, not clinical patients.

To be clear about what this video is doing: it is romanticizing an unregulated, injectable compound with serious risks while wrapping the danger in aspirational language. The "you'll risk burning your body to ash" line is not a warning, it is a sales pitch dressed as a caution. That framing matters when we evaluate the claims.

Does the science back this up?

Partly, but the dramatic framing distorts the actual biology in ways that matter. IGF-1 is a real and well-studied anabolic hormone, but the claim that it "rewrites your biology" overstates what the evidence shows in healthy adults using exogenous IGF-1.

IGF-1, or insulin-like growth factor 1, is produced primarily in the liver in response to growth hormone signaling. It does drive muscle protein synthesis and cell proliferation, which is why it has legitimate clinical applications, including treatment of growth failure in children with severe IGF-1 deficiency (the drug mecasermin, brand name Increlex). In that population, effects are meaningful. But the leap from pediatric deficiency treatment to performance enhancement in healthy adults is not supported by robust human trial data. A 2013 review by Higgins et al. in the British Journal of Sports Medicine found that exogenous IGF-1 use in healthy adults showed inconsistent anabolic effects and significant adverse event profiles. The "explosion" of growth @diagoslab describes is not what controlled studies show.

What did they get wrong, and what did they get right?

They got the hypoglycemia risk right. That is the one factually grounded claim in this video. IGF-1 has structural similarity to insulin and binds insulin receptors, meaning it can cause significant drops in blood glucose. This is well-documented and is actually the primary safety concern in clinical settings. A 2009 study by Clemmons in Endocrinologic and Metabolic Clinics of North America explicitly flags hypoglycemia as the dose-limiting adverse effect of IGF-1 therapy.

What they got wrong is significant. The phrase "absolute mutation" has no scientific basis. IGF-1 does not cause genetic mutation in the sense the word implies. The creator likely means morphological change, but using "mutation" is irresponsible framing that will be misunderstood. More importantly, the claim that users will look "manufactured" rather than natural ignores that most published data on supraphysiologic IGF-1 in athletes is case-report level, not controlled trial evidence. The risks are real but not fully characterized. Presenting this as a known, predictable transformation is misleading. There is also emerging concern linking chronically elevated IGF-1 to cancer promotion, a fact the video skips entirely. A 2012 meta-analysis by Rowlands et al. in Cancer Epidemiology, Biomarkers and Prevention found associations between elevated circulating IGF-1 and colorectal, prostate, and premenopausal breast cancer risk.

What should you actually know?

IGF-1 is not a peptide you experiment with based on a TikTok video. It is a Schedule III adjacent compound with a narrow clinical use case and a meaningful adverse event profile that includes hypoglycemia, edema, jaw growth, and potential long-term cancer risk elevation.

Here is what the evidence actually supports. Exogenous IGF-1 does have anabolic signaling effects. Hypoglycemia is a documented and serious risk. Long-term supraphysiologic IGF-1 exposure has been associated with cancer risk in epidemiological data. The "superhuman" framing in performance enhancement communities is not matched by controlled human trial data showing consistent, dramatic effects in healthy adults. If you are evaluating IGF-1 as part of a supervised, clinical longevity or hormonal optimization protocol, that is a conversation to have with a licensed provider who can order baseline labs, monitor IGF-1 serum levels, and assess your individual risk profile. It is not something to dose based on vibes from a viral video with 553,000 views.

• Hypoglycemia risk is real and can be acute and severe.
• Cancer risk association in long-term elevated IGF-1 is supported by epidemiological data.
• Exogenous IGF-1 is not approved for healthy adult use in the United States.
• The aesthetic outcomes described are not replicated in controlled human trials.